Arcus Biosciences (RCUS) EBIAT (2017 - 2025)
Historic EBIAT for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to -$135.0 million.
- Arcus Biosciences' EBIAT fell 4673.91% to -$135.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$341.0 million, marking a year-over-year decrease of 2629.63%. This contributed to the annual value of -$283.0 million for FY2024, which is 781.76% up from last year.
- According to the latest figures from Q3 2025, Arcus Biosciences' EBIAT is -$135.0 million, which was down 4673.91% from -$112.0 million recorded in Q1 2025.
- Arcus Biosciences' EBIAT's 5-year high stood at $279.5 million during Q4 2021, with a 5-year trough of -$135.0 million in Q3 2025.
- Moreover, its 5-year median value for EBIAT was -$75.5 million (2021), whereas its average is -$58.4 million.
- Within the past 5 years, the most significant YoY rise in Arcus Biosciences' EBIAT was 63909.71% (2021), while the steepest drop was 437963.78% (2021).
- Over the past 5 years, Arcus Biosciences' EBIAT (Quarter) stood at $279.5 million in 2021, then tumbled by 123.97% to -$67.0 million in 2022, then decreased by 20.9% to -$81.0 million in 2023, then dropped by 16.05% to -$94.0 million in 2024, then crashed by 43.62% to -$135.0 million in 2025.
- Its EBIAT stands at -$135.0 million for Q3 2025, versus -$112.0 million for Q1 2025 and -$94.0 million for Q4 2024.